Adipotide (FTPP): Fat-Cell Ablation and the Kidney Problem

At a Glance

Adipotide is the most conceptually radical weight-loss compound ever to reach a human trial, and understanding why it stalled is more instructive than any dosing table.

Every other drug in this field works through appetite, absorption or energy expenditure. Adipotide works by killing tissue. It carries a homing sequence that docks onto prohibitin, a protein expressed on the blood vessels supplying white fat, and delivers a payload that triggers apoptosis in those vessels. Starve the fat of its blood supply and the fat tissue itself disappears. In mice this reversed established obesity. In obese monkeys it produced rapid weight loss and improved insulin resistance, with MRI and DXA confirming a marked reduction in white adipose tissue [1, 2].

The honest verdict: adipotide’s efficacy was never the problem. The same paper that reported the monkey results also reported predictable, dose-related changes in renal proximal tubule function across three species, and the single first-in-human trial — in patients with metastatic prostate cancer, not otherwise healthy people with obesity — was terminated at the investigator’s request with four patients enrolled and no published results. Fifteen years later, nothing has superseded that.

That is the shape of the evidence: a brilliant mechanism, animal proof of concept, a kidney signal as the dose-limiting toxicity, and a human programme that stopped before it answered anything.

How it works

The mechanism has three parts, and the design is genuinely elegant.

1. Vascular zip codes. Different tissues express distinguishable protein signatures on their blood vessels. Phage-display screening identified the peptide CKGGRAKDC as homing specifically to white fat vasculature, and established that it binds prohibitin, a multifunctional membrane protein that the same work proposed as a vascular marker of adipose tissue. Prohibitin is also expressed in the blood vessels of human white fat, which is what made translation plausible [1].

2. A proapoptotic payload. The (KLAKLAK)₂ sequence, built from D-amino acids so it resists proteolysis, is a membrane-disrupting peptide that is relatively inert outside cells but destroys mitochondrial membranes once internalised, triggering programmed cell death. The payload came from earlier work on targeted proapoptotic peptides in cancer [3].

3. Ligand-directed delivery. Joined together, the homing motif concentrates the payload at the fat vasculature. Ablating those vessels causes resorption of established white adipose tissue, which in mice normalised metabolism and reversed obesity without adverse effects detectable in that model [1].

Two features matter clinically. The effect is not appetite-mediated — in the mouse work, obesity reversed without food intake being the driver. And it is destructive rather than regulatory, which makes the relevant safety questions cytotoxic ones: what else expresses the target, where does the peptide accumulate, and which tissue pays the price. The answer to the third question turned out to be the kidney.

What the evidence shows

Mouse: proof of concept

Kolonin and colleagues (Nature Medicine 2004) showed that CKGGRAKDC associates with prohibitin, established prohibitin as a vascular marker of adipose tissue, and demonstrated that targeting a proapoptotic peptide to prohibitin in the adipose vasculature caused ablation of white fat. Resorption of established white adipose tissue and normalisation of metabolism produced rapid obesity reversal without detectable adverse effects in that model [1].

Monkey: efficacy and the kidney signal in one paper

Barnhart and colleagues (Science Translational Medicine 2011) evaluated adipotide in obese Old World monkeys — the key translational step, since rodent-to-primate differences had sunk earlier anti-obesity strategies. The findings:

• Targeted apoptosis within the blood vessels of white adipose tissue, as intended.
• Rapid weight loss and improved insulin resistance.
• MRI and DXA confirmed a marked reduction in white adipose tissue.
• At the experimentally determined optimal doses, monkeys from three different species displayed predictable and reversible changes in renal proximal tubule function [2].

That last finding is the pivot point of the whole adipotide story. The authors presented reversibility and predictability as reassuring, and they were right that dose-related, recovering toxicity is better than idiosyncratic, irreversible injury. But it also defines the therapeutic window: the doses that remove fat are the doses that affect the kidney’s reabsorptive machinery.

Why the proximal tubule? Small peptides are filtered, then reabsorbed and catabolised there, concentrating a cytotoxic payload in exactly the cells least able to avoid it. This is a known failure mode for peptide therapeutics, not an adipotide quirk.

Human: one trial, terminated

The first-in-human study (ClinicalTrials.gov NCT01262664) was a phase 1 evaluation of a single cycle of prohibitin-targeting peptide-1 at MD Anderson Cancer Center, in patients with metastatic prostate cancer and obesity. Registry facts:

Choosing oncology patients for a first-in-human cytotoxic obesity drug was ethically coherent — you do not give a proapoptotic peptide to healthy volunteers. It also means the trial was never designed to answer the obesity question, and it stopped long before it could answer the safety one.

What no evidence exists for

No published human pharmacokinetics, no human weight-loss data, no human renal safety data, and no long-term animal data on what happens to fat tissue or to metabolic regulation after a substantial portion of the adipose vascular bed has been destroyed. That last question is not idle: adipose tissue is an endocrine organ, and ablating it is not obviously equivalent to losing fat through caloric deficit.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

What that table actually tells you. The only human dose on record is a starting dose chosen to be safe rather than effective, in a trial that stopped before escalation. Nobody knows the dose at which adipotide removes fat in a person, and nobody knows the dose at which it injures a human kidney. Those two numbers are the entire clinical question, and both are unknown.

The specific hazard of self-dosing this compound. Proximal tubule injury is clinically silent at onset. It does not hurt. It shows up as a rising creatinine, a falling eGFR, or low-molecular-weight proteinuria on a urine test nobody orders unless they are looking for it. Someone running a four-week course on a vendor protocol would have no symptom to warn them before the damage was measurable. In the monkey study the changes were reversible — in monkeys, at controlled doses, with veterinary monitoring. None of those three conditions applies to a self-administered research chemical.

Stacks. Protocols pairing adipotide with GLP-1 agonists or GH-axis peptides circulate. There is no data on any combination, and pairing a nephrotoxic cytotoxic peptide with an agent whose commonest adverse effects are vomiting and dehydration — a recognised precipitant of acute kidney injury — is a specifically poor idea.

For anyone proceeding regardless, the minimum monitoring would be baseline and interval creatinine, eGFR, cystatin C and urine albumin-to-creatinine ratio, plus a low-molecular-weight protein marker such as urinary beta-2-microglobulin or retinol-binding protein, which is what actually detects proximal tubule dysfunction. Injection technique in general: peptide injection guide.

What people report: what works and what doesn’t

Adipotide has no legitimate clinical use and no published human efficacy, so the anecdotal record is both thin and unusually unreliable. Sources: the published animal and registry record above; the open community record on r/Peptides; and vendor protocol pages. Patterns only — no individual account is treated as evidence.

Reported to work

• Rapid weight loss over two to four weeks is the recurring claim. It is consistent in direction with the animal data, entirely unverified in people, and generally reported without any body-composition measurement.

Mixed or unclear

• Whether reported weight loss reflects fat ablation, fluid shifts, reduced appetite or something else. With no DXA, no imaging and no pharmacokinetics, this is unresolvable from anecdote.
• Whether material sold as “adipotide” is the molecule at all. This is a conjugate with a D-amino-acid domain — considerably harder to synthesise correctly than a simple linear peptide, and correspondingly easier to get wrong or substitute.

Reported not to work / disappointing

• Durability. Regain after stopping is commonly described, which raises the question the animal work never answered in a long-lived species: whether ablated adipose vasculature regenerates.
• Side effects described include thirst, increased urination, nausea, lethargy and dehydration. Thirst and polyuria are what proximal tubule dysfunction looks like from the outside, which makes those the most clinically significant reports in the whole anecdotal record.
• Several community accounts describe stopping specifically because of a raised creatinine on bloodwork. That is the single most useful anecdote available about this compound.

What a properly designed trial would need to show: a dose producing measurable fat-mass reduction on imaging in humans, with renal tubular function tracked by sensitive markers rather than creatinine alone, and demonstrated recovery after the cycle ends. The trial designed to begin answering this stopped after four patients; nobody has restarted it.

Safety and side effects

The dose-limiting toxicity is renal. This is the central safety fact: across three monkey species, the optimal fat-ablating doses produced predictable, reversible changes in renal proximal tubule function [2]. Reversible in a monitored primate study does not establish reversible in an unmonitored human one.

Cytotoxic class risk. A proapoptotic payload delivered systemically raises questions an appetite-suppressing drug does not: off-target apoptosis wherever the target is expressed or the payload accumulates, the consequences of a large volume of dying tissue, and inflammatory sequelae. None of this has been characterised in humans.

Unknowns that matter more than usual. The endocrine consequences of destroying adipose tissue rather than depleting it; whether adipose vasculature regenerates; immunogenicity of a D-amino-acid conjugate; and interactions with anything nephrotoxic, from NSAIDs and aminoglycosides to iodinated contrast.

Cancer-adjacent framing, stated plainly. Adipotide’s only human exposure was in patients with metastatic prostate cancer, and the payload derives from an anticancer targeted-peptide programme [3]. It has not been shown to treat cancer in humans, and it has not been shown to cause cancer. The trial setting reflects the ethics of first-in-human cytotoxic dosing, nothing more.

Grey-market risk. Unverified identity, purity, sterility and concentration, for a complex conjugate with a narrow, renally defined therapeutic window. See peptide sourcing.

My position. Of everything covered in this library, adipotide is where the gap between mechanistic elegance and clinical readiness is widest. I would not use it, and I would not support someone using it outside a monitored trial — not because the biology is unconvincing, but because the one dose-limiting toxicity we know about is one you cannot feel.

Legal and regulatory status

United States. No FDA approval for any indication. Adipotide does not appear on the 503A category 1 list, so no compounding enforcement-discretion pathway applies — see the FDA 2026 compounding update. The only registered human study was terminated and never reported results.

European Union and Germany. No EMA authorisation, no clinical availability, no pharmacy supply.

Sport. A non-approved substance falls under WADA category S0: prohibited at all times, in and out of competition. See peptides and WADA rules.

How it fits: destroying fat vs regulating appetite

The comparison makes the opportunity cost obvious. In 2011, when the monkey paper appeared, pharmacological weight loss meant single-digit percentages, and adipotide’s destructive approach looked like a reasonable gamble against a therapeutic dead end. That context is gone. An approved weekly injection now produces roughly a fifth of body weight in a 2,500-person randomised trial with well-characterised safety [5], which means the risk calculus that once justified exploring fat-cell ablation no longer holds for an individual patient.

Where the science still deserves attention is in oncology and vascular targeting. Ligand-directed delivery of a payload to a tissue-specific vascular marker remains an important idea, and prohibitin remains a real target. The lesson of adipotide is not that the concept failed — it is that a cytotoxic payload and the renal proximal tubule are a hard combination to reconcile, and that no amount of mechanistic elegance substitutes for a completed dose-escalation study.

Related Articles

• Tirzepatide: The Dual GIP/GLP-1 Agonist in Full — the approved alternative that defines the current risk-benefit baseline.
• HGH Fragment 176-191: The Unmodified Fragment vs AOD-9604 — the other grey-market fat-loss peptide, with a very different risk profile.
• AOD 9604 Peptide: The hGH Fragment for Fat Loss and Tissue Repair — what a completed human programme for a fat-loss peptide looks like.
• FOXO4-DRI and Senolytic Peptides: Mouse Data, Zero Human Trials — the same evidence pattern in another cell-death-based strategy.
• Are Peptides Legal? A 2026 Regulatory Guide — where unapproved research peptides sit legally.
• Peptide Sourcing: Pharmaceutical-Grade vs Grey Market — why a complex conjugate peptide is the worst case for unverified supply.